Extracts from "clinical evidence": age related macular degeneration.
作者信息
Arnold J J, Sarks S H
机构信息
Aberdeen Royal Hospitals NHS Trust, Aberdeen.
出版信息
BMJ. 2000 Sep 23;321(7263):741-4. doi: 10.1136/bmj.321.7263.741.
Abstract
摘要
相似文献
1
Extracts from "clinical evidence": age related macular degeneration.摘自《临床证据》：年龄相关性黄斑变性
BMJ. 2000 Sep 23;321(7263):741-4. doi: 10.1136/bmj.321.7263.741.
2
Age related macular degeneration.
Clin Evid. 2005 Jun(13):762-75.
3
Age related macular degeneration.
Clin Evid. 2004 Jun(11):819-34.
4
Age related macular degeneration.
Clin Evid. 2003 Dec(10):727-43.
5
Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy.年龄相关性黄斑变性中黄斑下脉络膜新生血管的治疗：聚焦维替泊芬光动力疗法的临床应用
Br J Ophthalmol. 2001 Apr;85(4):483-95. doi: 10.1136/bjo.85.4.483.
6
Age related macular degeneration.
Clin Evid. 2006 Jun(15):877-88.
7
[New therapeutic aspects in age-related macular degeneration].[年龄相关性黄斑变性的新治疗方面]
Med Clin (Barc). 2007 Nov 10;129(17):658-9. doi: 10.1157/13112103.
8
[Past, present, and future therapeutically options in age related macular degeneration].
Oftalmologia. 2002;53(2):5-8.
9
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.维替泊芬光动力疗法治疗年龄相关性黄斑变性的中心凹下脉络膜新生血管：两项随机临床试验的一年结果——TAP报告。年龄相关性黄斑变性光动力疗法（TAP）研究组
Arch Ophthalmol. 1999 Oct;117(10):1329-45.
10
Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand?维替泊芬与抗血管内皮生长因子（VEGF）药物联合治疗新生血管性年龄相关性黄斑变性：我们目前的进展如何？
Br J Ophthalmol. 2010 Feb;94(2):143-5. doi: 10.1136/bjo.2009.159863.
引用本文的文献
1
Transforming growth factor-beta inhibition reduces progression of early choroidal neovascularization lesions in rats: P17 and P144 peptides.转化生长因子-β抑制可减少大鼠早期脉络膜新生血管病变的进展：P17 和 P144 肽。
PLoS One. 2013 May 31;8(5):e65434. doi: 10.1371/journal.pone.0065434. Print 2013.
2
Genetic basis of inherited macular dystrophies and implications for stem cell therapy.遗传性黄斑营养不良的遗传基础及其对干细胞治疗的影响。
Stem Cells. 2009 Nov;27(11):2833-45. doi: 10.1002/stem.159.
3
Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study.新生血管性年龄相关性黄斑变性患者的疾病负担、视力损害及健康资源利用情况：一项五国横断面研究英国队列的结果
Br J Ophthalmol. 2007 Oct;91(10):1303-7. doi: 10.1136/bjo.2007.116939. Epub 2007 May 15.
4
Dietary analysis and patterns of nutritional supplement use in normal and age-related macular disease affected subjects: a prospective cross-sectional study.正常及年龄相关性黄斑病变受试者的饮食分析与营养补充剂使用模式：一项前瞻性横断面研究。
Nutr J. 2004 Sep 28;3:16. doi: 10.1186/1475-2891-3-16.
5
Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review.维替泊芬光动力疗法是有效的，但其效果有多大？一项系统评价的结果。
Br J Ophthalmol. 2004 Feb;88(2):212-7. doi: 10.1136/bjo.2003.019471.
6
A randomised controlled trial investigating the effect of nutritional supplementation on visual function in normal, and age-related macular disease affected eyes: design and methodology [ISRCTN78467674].一项随机对照试验，研究营养补充剂对正常眼睛和年龄相关性黄斑病变患眼视觉功能的影响：设计与方法 [国际标准随机对照试验编号：ISRCTN78467674]
Nutr J. 2003 Oct 10;2:12. doi: 10.1186/1475-2891-2-12.
7
Age related macular degeneration.年龄相关性黄斑变性
BMJ. 2003 Mar 1;326(7387):485-8. doi: 10.1136/bmj.326.7387.485.
8
How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?在英国，年龄相关性黄斑变性导致的视力丧失负担有多大？
Br J Ophthalmol. 2003 Mar;87(3):312-7. doi: 10.1136/bjo.87.3.312.
9
Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement.降胆固醇药物与年龄相关性黄斑病变风险：采用累积暴露量测量的前瞻性队列研究
BMJ. 2003 Feb 1;326(7383):255-6. doi: 10.1136/bmj.326.7383.255.
本文引用的文献
1
Radiation-associated choroidal neovasculopathy.
Ophthalmology. 1999 Dec;106(12):2254-60. doi: 10.1016/S0161-6420(99)90524-9.
2
A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Radiation Therapy for Age-related Macular Degeneration.一项关于新生血管性年龄相关性黄斑变性放射治疗的前瞻性、随机、双盲试验（RAD研究）。年龄相关性黄斑变性的放射治疗。
Ophthalmology. 1999 Dec;106(12):2239-47. doi: 10.1016/s0161-6420(99)90522-5.
3
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.维替泊芬光动力疗法治疗年龄相关性黄斑变性的中心凹下脉络膜新生血管：两项随机临床试验的一年结果——TAP报告。年龄相关性黄斑变性光动力疗法（TAP）研究组
Arch Ophthalmol. 1999 Oct;117(10):1329-45.
4
Randomized trial of radiation for age-related macular degeneration.
Am J Ophthalmol. 1999 May;127(5):574-8. doi: 10.1016/s0002-9394(99)00038-0.
5
Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye.
Curr Opin Ophthalmol. 1998 Jun;9(3):38-46. doi: 10.1097/00055735-199806000-00007.
6
Age-related macular degeneration: a review of experimental treatments.
Surv Ophthalmol. 1998 Sep-Oct;43(2):134-46. doi: 10.1016/s0039-6257(98)00014-9.
7
A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation.
Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):321-5. doi: 10.1007/s004170050085.
8
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.组织型纤溶酶原激活剂辅助手术切除年龄相关性黄斑变性患者的黄斑下脉络膜新生血管：一项随机双盲试验。
Ophthalmology. 1997 Nov;104(11):1847-51; discussion 1852. doi: 10.1016/s0161-6420(97)30018-9.
9
Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.干扰素α-2a对年龄相关性黄斑变性继发脉络膜新生血管患者无效。一项前瞻性随机安慰剂对照临床试验的结果。黄斑变性药物治疗研究组。
Arch Ophthalmol. 1997 Jul;115(7):865-72. doi: 10.1001/archopht.1997.01100160035005.
10
Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group.年龄相关性黄斑变性继发中心凹旁或中心凹下脉络膜新生血管患者对侧眼发生脉络膜新生血管的危险因素。黄斑光凝研究组
Arch Ophthalmol. 1997 Jun;115(6):741-7. doi: 10.1001/archopht.1997.01100150743009.
Zotero 插件